ArticleThe journal of allergy and clinical immunology. Global2025
Clinical validity of dried blood spot assay for the measurement of functional C1 inhibitor in angioedema due to C1 inhibitor deficiency.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema.Allergy · 2026Guideline
- Hereditary angioedema: on-demand treatment and long-term prophylaxis-a global reality.Clinical and experimental immunology · 2026Review
- Evaluating functional C1INH with multiple laboratory methods across Hereditary Angioedema types.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Functional C1 inhibitor (fC1INH) is a key biomarker for the diagnosis of hereditary angioedema due to C1 inhibitor (C1INH) deficiency. A novel fC1INH assay from dried blood spot (DBS) reduces practical fC1INH testing limitations versus conventional fC1INH assays, but its sensitivity and specificity have not yet been characterized. Objective: We sought to assess the sensitivity and specificity of fC1INH DBS assay and conventional fC1INH ELISA and chromogenic assay. Methods: fC1INH DBS assay was performed in samples from 30 patients with previously diagnosed recurrent angioedema due to C1INH deficiency and from 100 healthy controls. Whole blood samples were spotted onto blotting paper and dried for 3 hours or longer, and then fC1INH from DBS was measured through its C1s protease inhibitory activity using liquid chromatography tandem mass spectrometry. fC1INH ELISA and chromogenic assays were performed by reanalyzing a subset of 29 patients and 50 healthy controls. Sensitivity and specificity were evaluated using a negative sample mean - 1.96 SD cutoff. Results: fC1INH DBS assay had a sensitivity of 0.93, a specificity of 0.97, and area under the curve of the receiver-operating characteristic curve of 0.996 (95% CI, 0.989-1.000). In the subset, DBS and chromogenic assay had similar sensitivity (DBS, 1.00; chromogenic assay, 0.97) and specificity (DBS, 0.94; chromogenic assay, 1.00); ELISA sensitivity was lower (0.62) and specificity similar (1.00). Conclusions: fC1INH DBS assay had similar sensitivity and specificity when contrasted with fC1INH chromogenic assay. Because of its easier sample collection and logistic benefits, fC1INH DBS assay may allow more accessible hereditary angioedema diagnostic testing, especially in underserved regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.